Advanced nutraceutical solution for the successful management of hemorrhoidal crises
The acute phase of hemorrhoids can be really debilitating, therefore affected patients need decisive therapies to manage this condition and relieving symptoms.
Emospid® contains highly standardized plant extracts boosted by advanced pharmaceutical technologies to provide a rapid relief. A clinical study confirms its effectiveness in the management of acute hemorrhoidal crises.
Hemorrhoidal crises: a real pain in the backside
Hemorrhoids, also known as piles, are swollen veins located in the lower rectum or anus.
The symptoms of hemorrhoids can vary depending on the location and severity of the condition. Internal hemorrhoids may not cause any symptoms, but can sometimes cause bleeding during bowel movements, as well as a feeling of incomplete evacuation of stool. External hemorrhoids, on the other hand, can cause pain, itching, swelling, and difficulty sitting or standing.
In severe cases, surgical procedures may be necessary to remove the hemorrhoids.
The acute phase of hemorrhoids is referred to as Hemorrhoidal crises, also known as hemorrhoid flare-ups or attacks. During hemorrhoidal crisis, hemorrhoids are inflamed or swollen and can become painful, leading to bleeding, itching, and difficulty passing stool. In some cases, a blood clot may form within the hemorrhoid, causing a thrombosed hemorrhoid, which can be extremely painful.
In short, the impact of hemorrhoidal crisis on patients’ quality of life can be so strong to impair activities of daily living. For this reason, people suffering from hemorrhoidal crises commonly don’t wait to make an appointment with a specialist and seek an appropriate treatment to relieve the symptoms that should be safe, side-effect free and possibly natural.
With this aim in mind, PharmExtracta launched Emospid®, already in 2006, a food supplement that offers a solid help in managing hemorrhoidal crises and, more generally, in keeping hemorrhoids at bay, also avoiding or delaying surgical procedures in severe cases.
Formulation rationale of Emospid®
Emospid® is a food supplement coming in 3-layer-tablets containing 3 highly-selected plant extracts that have been engineered with biopharmaceutical technologies to control their release and create a synergistic activity that is able to provide a great effectiveness, comparable to that of a drug:
1) Leucoselect Phytosome®, with NORMAL RELEASE (45 minutes) → PROTECTIVE ACTIVITY
Leucoselect Phytosome® is a proprietary ingredient that employs the Phytosome® technology to increase the bioavailability and absorption of the active compounds in the extract.
Research has suggested that the proanthocyanidins found in grape seed extract may have antioxidant and anti-inflammatory properties and may help improve blood vessel health protecting vascular walls from oxidation e from enzymatic aggression.
2) Triterpenes found in gotu kola (Centella asiatica), with SLOW RELEASE (8 hours) → RESTORING ACTIVITY
According to research these components may have a number of health benefits, including promoting wound healing, reducing inflammation, and improving circulation.
Studies have shown that triterpenes from gotu kola can increase collagen production in vascular smooth muscle cells, which can help strengthen blood vessel walls and support the restoration of damaged blood vessel tunics.
3) Mirtoselect®, with NORMAL RELEASE → REPAIRING ACTIVITY
this is another proprietary extract made from bilberries (Vaccinium myrtillus), which are a type of small, dark berry that are very rich in compounds with potential benefits for cardiovascular health.
More specifically, Mirtoselect® contains high levels of anthocyanins, which are a type of flavonoid that are known for their antioxidant properties and have been shown to have potential benefits for blood vessel health, including improving blood flow and reducing inflammation.
Clinical evidence on Emospid® effectiveness in the management of acute hemorrhoidal crises
The effectiveness of Emospid® in the management of acute hemorrhoidal crises was evaluated in in the context of the clinical study Clinical effectiveness of a highly standardized and bioavailable mixture of flavonoids and triterpenes in the management of acute hemorroidal crisis.
The observation included patients with a diagnosis of hemorrhoidal crisis that were randomized to receive Emospid® or a micronized mixture of diosmin and hesperidin (MMDH) corresponding to a well-known medication that is commonly used for this issue.
The activity of Emospid® was compared with the one of MMDH assessing several symptoms associated to the pathology, among which the main ones were hemorrhoidal grade, bleeding, and pain.
The study results show that Emospid®, used for 7 days in patients with hemorrhoidal crisis, reduced the hemorrhoidal pathology by 1 degree of severity in 87% of patients.
- blocked bleeding in 76%
- eliminated pain in 87% of patients
- significantly improved all the other symptoms related to this pathology (internal and external oedema, internal and external thrombosis, bleeding, bleeding intensity, pain, itching, defecation problems and urgency, tenesm, mucus in stools and sphinterial tone)
with a performance that can be considered superior to that of MMDH.
